#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4292	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2357	529.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1481	1481	C	637	C,G	577,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6792	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4309	472.6	0	.	n	.	0	T695C	SNP	695	695	T	1394	1394	C	531	C,A	471,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6792	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4309	472.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	2036	2036	A	550	A,T,C	508,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6792	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4309	472.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2670	2670	C	628	C	570	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6792	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4309	472.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2744	2744	A	653	A	592	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6792	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4309	472.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3296	3296	C	618	C,T	537,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	886	folP	852	852	100.0	folP.l15.c4.ctg.1	2038	130.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1224	1226	AGC	195;193;193	A;G;C	181;177;173	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1888	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3820	148.1	1	SNP	p	S91F	0	.	.	271	273	TCC	792	794	TCC	172;172;171	T;C;C	152;155;154	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1888	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3820	148.1	1	SNP	p	D95G	0	.	.	283	285	GAC	804	806	GAC	169;168;169	G,T;A;C	156,1;153;150	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1888	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3820	148.1	1	SNP	p	D95N	0	.	.	283	285	GAC	804	806	GAC	169;168;169	G,T;A;C	156,1;153;150	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	768	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1783	129.2	0	.	p	.	0	A40P	NONSYN	118	120	GCC	673	675	CCC	168;169;168	C,T;C;C	152,1;156;150	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	768	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1783	129.2	1	SNP	p	G45D	0	.	.	133	135	GGC	688	690	GGC	166;166;165	G;G;C,G	154;153;152,1	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1846	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3296	167.4	1	SNP	p	D86N	0	.	.	256	258	GAC	746	748	GAC	183;183;183	G;A,C;C	167;155,2;165	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1846	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3296	167.4	1	SNP	p	S87W	0	.	.	259	261	AGT	749	751	AGT	182;183;181	A,C,T;G,T;T	158,1,1;170,1;163	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1846	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3296	167.4	1	SNP	p	S87I	0	.	.	259	261	AGT	749	751	AGT	182;183;181	A,C,T;G,T;T	158,1,1;170,1;163	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1846	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3296	167.4	1	SNP	p	S87R	0	.	.	259	261	AGT	749	751	AGT	182;183;181	A,C,T;G,T;T	158,1,1;170,1;163	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1846	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3296	167.4	1	SNP	p	S88P	0	.	.	262	264	TCC	752	754	TCC	180;182;183	T,G;C,T;C	164,1;165,1;169	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1656	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3178	156.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1834	1836	GGC	226;223;223	G;G;C,T,A	208;201;197,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1524	1526	GCA	218;217;216	G;C,T;A,C	196;194,1;195,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1527	1529	ATC	213;213;215	A;T;C	197;188;202	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1539	1541	GTG	213;214;214	G;T;G	195;196;197	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1539	1541	GTG	213;214;214	G;T;G	195;196;197	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2043	2045	ACC	156;157;156	A;C;C	145;141;145	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2097	2099	GCG	161;161;161	G;C,G;G,C	142;124,1;127,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2097	2099	GCG	161;161;161	G;C,G;G,C	142;124,1;127,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2220	2222	GGC	153;154;155	G;G;C	136;141;135	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2229	2231	GGC	157;156;156	G,T;G;C	134,1;143;142	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1270	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3008	126.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2247	2249	CCG	156;155;155	C,G;C;G,T,C	135,4;143;133,2,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1546	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3776	122.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	884	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2297	115.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	861	861	C	136	C	126	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	92	porB1a	984	188	90.1	porB1a.l6.c4.ctg.1	1374	20.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1211	1213	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	92	porB1a	984	188	90.1	porB1a.l6.c4.ctg.1	1374	20.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1214	1216	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	92	porB1a	984	188	90.1	porB1a.l6.c4.ctg.1	1374	20.0	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1226	1228	GTT	4;4;4	G;T;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	92	porB1a	984	188	90.1	porB1a.l6.c4.ctg.1	1374	20.0	0	.	p	.	0	A225S	NONSYN	673	675	GCC	1235	1237	TCC	4;4;4	T,G;C;C	1,3;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	92	porB1a	984	188	90.1	porB1a.l6.c4.ctg.1	1374	20.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1238	1240	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	92	porB1a	984	188	90.1	porB1a.l6.c4.ctg.1	1374	20.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1261	1263	GGA	4;4;4	G;G,T;A	4;0,3;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	92	porB1a	984	188	90.1	porB1a.l6.c4.ctg.1	1374	20.0	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1273	1273	G	4	G	4	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	0	.	p	.	0	F135L	NONSYN	403	405	TTT	985	987	CTT	163;164;163	C,G;T;T,G	147,1;144;144,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1009	1011	GGA	165;164;164	G,A;G,A;A	147,1;145,1;141	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1093	1095	GGT	145;145;148	G,T;G,A;T	132,1;130,1;137	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1147	1149	AGC	138;138;138	A,G;G,A;C	126,1;132,2;133	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1213	1213	T	133	T	123	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	1	SNP	p	G120K	0	.	.	358	360	GGT	940	942	GGT	180;181;180	G,A;G,A;T,G	159,1;157,1;151,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	1	SNP	p	A121N	0	.	.	361	363	GCC	943	945	GCC	179;177;176	G;C,T,A;C	154;153,1,1;152	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	764	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	2325	97.9	1	SNP	p	A121D	0	.	.	361	363	GCC	943	945	GCC	179;177;176	G;C,T,A;C	154;153,1,1;152	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2312	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5423	127.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2316	2318	AAT	152;153;153	A;A;T,G	132;133;131,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	276	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1337	61.5	1	SNP	p	V57M	1	.	.	169	171	ATG	699	701	ATG	111;111;111	A;T;G	99;101;100	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
